-
Something wrong with this record ?
Cell death in head and neck cancer pathogenesis and treatment
M. Raudenská, J. Balvan, M. Masařík
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
Freely Accessible Science Journals
from 2010
Nature Open Access
from 2010-01-01
PubMed Central
from 2010
Europe PubMed Central
from 2010
ProQuest Central
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Health & Medicine (ProQuest)
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
Springer Nature OA/Free Journals
from 2010-01-01
- MeSH
- Apoptosis drug effects MeSH
- Autophagy drug effects MeSH
- Drug Resistance, Neoplasm MeSH
- Squamous Cell Carcinoma of Head and Neck drug therapy genetics metabolism pathology MeSH
- Ferroptosis drug effects MeSH
- Genetic Heterogeneity MeSH
- Humans MeSH
- Tumor Microenvironment MeSH
- Head and Neck Neoplasms drug therapy genetics metabolism pathology MeSH
- Necroptosis drug effects MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyroptosis drug effects MeSH
- Regulated Cell Death drug effects MeSH
- Signal Transduction MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Many cancer therapies aim to trigger apoptosis in cancer cells. Nevertheless, the presence of oncogenic alterations in these cells and distorted composition of tumour microenvironment largely limit the clinical efficacy of this type of therapy. Luckily, scientific consensus describes about 10 different cell death subroutines with different regulatory pathways and cancer cells are probably not able to avoid all of cell death types at once. Therefore, a focused and individualised therapy is needed to address the specific advantages and disadvantages of individual tumours. Although much is known about apoptosis, therapeutic opportunities of other cell death pathways are often neglected. Molecular heterogeneity of head and neck squamous cell carcinomas (HNSCC) causing unpredictability of the clinical response represents a grave challenge for oncologists and seems to be a critical component of treatment response. The large proportion of this clinical heterogeneity probably lies in alterations of cell death pathways. How exactly cells die is very important because the predominant type of cell death can have multiple impacts on the therapeutic response as cell death itself acts as a second messenger. In this review, we discuss the different types of programmed cell death (PCD), their connection with HNSCC pathogenesis and possible therapeutic windows that result from specific sensitivity to some form of PCD in some clinically relevant subgroups of HNSCC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026066
- 003
- CZ-PrNML
- 005
- 20211026133232.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41419-021-03474-5 $2 doi
- 035 __
- $a (PubMed)33602906
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Raudenská, Martina $u Department of Physiology, Faculty of Medicine, Masaryk University / Kamenice 5, CZ-625 00, Brno, Czech Republic $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic
- 245 10
- $a Cell death in head and neck cancer pathogenesis and treatment / $c M. Raudenská, J. Balvan, M. Masařík
- 520 9_
- $a Many cancer therapies aim to trigger apoptosis in cancer cells. Nevertheless, the presence of oncogenic alterations in these cells and distorted composition of tumour microenvironment largely limit the clinical efficacy of this type of therapy. Luckily, scientific consensus describes about 10 different cell death subroutines with different regulatory pathways and cancer cells are probably not able to avoid all of cell death types at once. Therefore, a focused and individualised therapy is needed to address the specific advantages and disadvantages of individual tumours. Although much is known about apoptosis, therapeutic opportunities of other cell death pathways are often neglected. Molecular heterogeneity of head and neck squamous cell carcinomas (HNSCC) causing unpredictability of the clinical response represents a grave challenge for oncologists and seems to be a critical component of treatment response. The large proportion of this clinical heterogeneity probably lies in alterations of cell death pathways. How exactly cells die is very important because the predominant type of cell death can have multiple impacts on the therapeutic response as cell death itself acts as a second messenger. In this review, we discuss the different types of programmed cell death (PCD), their connection with HNSCC pathogenesis and possible therapeutic windows that result from specific sensitivity to some form of PCD in some clinically relevant subgroups of HNSCC.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a autofagie $x účinky léků $7 D001343
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a ferroptóza $x účinky léků $7 D000079403
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a nádory hlavy a krku $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D006258
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nekroptóza $x účinky léků $7 D000079302
- 650 _2
- $a pyroptóza $x účinky léků $7 D000069292
- 650 _2
- $a regulovaná buněčná smrt $x účinky léků $7 D000079404
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a dlaždicobuněčné karcinomy hlavy a krku $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D000077195
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Balvan, Jan $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University / Kamenice 5, CZ-625 00, Brno, Czech Republic
- 700 1_
- $a Masařík, Michal $u Department of Physiology, Faculty of Medicine, Masaryk University / Kamenice 5, CZ-625 00, Brno, Czech Republic. masarik@med.muni.cz $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00, Brno, Czech Republic. masarik@med.muni.cz $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University / Kamenice 5, CZ-625 00, Brno, Czech Republic. masarik@med.muni.cz $u BIOCEV, First Faculty of Medicine, Charles University, Prumyslova 595, CZ-252 50, Vestec, Czech Republic. masarik@med.muni.cz
- 773 0_
- $w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 12, č. 2 (2021), s. 192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33602906 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133238 $b ABA008
- 999 __
- $a ok $b bmc $g 1714933 $s 1146573
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 12 $c 2 $d 192 $e 20210218 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
- LZP __
- $a Pubmed-20211013
